Urokinase-type plasminogen activator
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain A； UniProt 156–178 Chain B； UniProt 179–431 | Fragment：SHORT CHAIN Fragment：CATALYTIC DOMAIN Mutation：N145A/S190A | CR9 2-{5-[AMINO(IMINIO)METHYL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}-6-[(2-METHYLCYCLOHEXYL)OXY]BENZENOLATE × 1 CIT CITRIC ACID × 2 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50 | Resolution 1.63 Å R-free 0.219 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1O5C | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1C5W STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 1999-12-22 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded | FLC CITRATE ANION × 3 ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml and
incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0, 1.4 mM
4-iodobenzo[b]thiophene-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging drops containing
equal volumes of protein-inhibitor solution (0.28 mM uPA/A145, 1.4 mM
inhibitor) and well solution (20 % 2-propanol, 20 % PEG 4K,
100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.94 Å R-free 0.211 |
| 1C5X STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 1999-12-22 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded | FLC CITRATE ANION × 3 ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml and
incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.4, 1.4 mM
4-iodobenzo[b]thiophene-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging drops
containing equal volumes of protein-inhibitor solution (0.28 mM uPA/A145,
1.4 mM inhibitor) and well solution (20 % 2-propanol, 20 % PEG 4K,
100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.75 Å R-free 0.244 |
| 1C5Y STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 1999-12-22 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded | FLC CITRATE ANION × 3 ESP THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml
and incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0,
5.0 mM thieno[2,3-b]pyridine-2-carboxamidine for 15 min on ice.
The complex was crystallized by vapor diffusion in hanging
drops containing equal volumes of protein-inhibitor solution
(0.28 mM uPA/A145, 1.4 mM inhibitor and well solution
(20 % 2-propanol, 20 % PEG 4K, 100 mM sodium citrate,
pH 6.5) sealed over the well.
|
Resolution 1.65 Å R-free 0.246 |
| 1C5Z STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 1999-12-22 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Not recorded | FLC CITRATE ANION × 3 BEN BENZAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；LMW human uPA/A145 was concentrated to 10 mg/ml
and incubated in 50 mM HEPES, 5.0 mM NaCl. pH 7.0,
5.0 mM benzamidne for 15 min on ice. The complex was
crystallized by vapor diffusion in hanging drops containing
equal volumes of protein-inhibitor solution (0.28 mM uPA/A145,
1.4 mM inhibitor) and well solution (20 % 2-propanol,
20 % PEG 4K, 100 mM sodium citrate, pH 6.5) sealed over the well.
|
Resolution 1.85 Å R-free 0.237 |
| 1EJN UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX Deposited 2000-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S | SO4 SULFATE ION × 1 AGB N-(1-ADAMANTYL)-N'-(4-GUANIDINOBENZYL)UREA × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.80 Å R-free 0.240 |
| 1F5L UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX Deposited 2000-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S | SO4 SULFATE ION × 2 AMR 3,5-DIAMINO-N-(AMINOIMINOMETHYL)-6-CHLOROPYRAZINECARBOXAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.250 |
| 1F92 UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX Deposited 2000-07-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
159–411（253 aa）
Fragment：B CHAIN
|
Mutation：C279S | SO4 SULFATE ION × 2 UKP [2,4,6-TRIISOPROPYL-PHENYLSULFONYL-L-[3-AMIDINO-PHENYLALANINYL]]-N'-BETA-ALANINYL-PIPERAZINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.2；298 K；pH 5.2, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å R-free 0.248 |
| 1FV9 Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole Deposited 2000-09-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：B CHAIN (16-243)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 172 2-AMINO-5-HYDROXY-BENZIMIDAZOLE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.15M LiSo4, 20% PEG 4000, succinate buffer, VAPOR DIFFUSION, HANGING DROP, temperature 18K
|
Resolution 3.00 Å |
| 1GI7 A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE Deposited 2001-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | 120 2-(2-OXO-1,2-DIHYDRO-PYRIDIN-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 CIT CITRIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.79 Å R-free 0.220 |
| 1GI8 A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE Deposited 2001-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 BMZ 2-(2-HYDROXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.75 Å R-free 0.254 |
| 1GI9 A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE Deposited 2001-01-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–423（245 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | 123 2-(2-HYDROXY-5-METHOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 CIT CITRIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.80 Å R-free 0.238 |
| 1GJ7 ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 132 6-CHLORO-2-(2-HYDROXY-BIPHENYL-3-YL)-1H-INDOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.50 Å R-free 0.230 |
| 1GJ8 ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 133 6-FLUORO-2-(2-HYDROXY-3-ISOBUTOXY-PHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.64 Å R-free 0.221 |
| 1GJ9 ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-30 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 134 6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.80 Å R-free 0.222 |
| 1GJA ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 135 N-(4-CARBAMIMIDOYL-PHENYL)-2-HYDROXY-BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.56 Å R-free 0.209 |
| 1GJB ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 130 2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.90 Å R-free 0.259 |
| 1GJC ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-04-27 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 130 2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.73 Å R-free 0.242 |
| 1GJD ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS Deposited 2001-05-03 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 136 N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.75 Å R-free 0.189 |
| 1KDU SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASE Deposited 1993-07-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
69–153（85 aa）
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1LMW LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone) Deposited 1995-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Chain B
179–431（253 aa）
|
Not recorded | 0GJ L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.50 Å |
| 1LMW LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone) Deposited 1995-07-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
156–178（23 aa）
Chain D
179–431（253 aa）
|
Not recorded | 0GJ L-alpha-glutamyl-N-{(1S)-4-{[amino(iminio)methyl]amino}-1-[(1S)-2-chloro-1-hydroxyethyl]butyl}glycinamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.50 Å |
| 1O3P Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine Protease Inhibitors Deposited 2003-03-06 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A | CIT CITRIC ACID × 2 655 2-{5-[AMINO(IMINIO)METHYL]-1H-BENZIMIDAZOL-2-YL}-6-(CYCLOPENTYLOXY)BENZENOLATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.50
|
Resolution 1.81 Å R-free 0.249 |
| 1O5A Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) Deposited 2003-09-09 | Different ligand/ion Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A/S190A | 696 3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-1,1'-BIPHENYL-2-OLATE × 1 CIT CITRIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50
|
Resolution 1.68 Å R-free 0.245 |
| 1O5B Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala190 Protease (Ala190 uPA) Deposited 2003-09-09 | Different ligand/ion Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
156–178（23 aa）
Fragment：SHORT CHAIN
Chain B
179–431（253 aa）
Fragment：CATALYTIC DOMAIN
|
Mutation：N145A/S190A | ESI 4-IODOBENZO[B]THIOPHENE-2-CARBOXAMIDINE × 1 CIT CITRIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；2-propanol, PEG 4000, pH 6.5, vapor diffusion at 298 K, pH 6.5, pH 6.50
|
Resolution 1.85 Å R-free 0.240 |
| 1OWD Substituted 2-Naphthamidine inhibitors of urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | 497 6-[AMINO(IMINO)METHYL]-N-[(4R)-4-ETHYL-1,2,3,4-TETRAHYDROISOQUINOLIN-6-YL]-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.32 Å R-free 0.313 |
| 1OWE Substituted 2-Naphthamidine inhibitors of urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | SO4 SULFATE ION × 3 675 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.236 |
| 1OWH Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | SO4 SULFATE ION × 3 239 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.61 Å R-free 0.265 |
| 1OWI Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | 426 6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.93 Å R-free 0.349 |
| 1OWJ Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | 155 6-[(Z)-AMINO(IMINO)METHYL]-N-(1-ISOPROPYL-3,4-DIHYDROISOQUINOLIN-7-YL)-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 3.10 Å R-free 0.344 |
| 1OWK Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2003-03-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：residues 179-423
|
Not recorded | 303 6-[(Z)-AMINO(IMINO)METHYL]-N-(1-ISOPROPYL-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.80 Å R-free 0.236 |
| 1SC8 Urokinase Plasminogen Activator B-Chain-J435 Complex Deposited 2004-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S | SO4 SULFATE ION × 2 2IN N-(BENZYLSULFONYL)SERYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}GLYCINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, litium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.240 |
| 1SQA Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2004-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
|
Not recorded | SO4 SULFATE ION × 3 UI1 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-4-(PYRIMIDIN-2-YLAMINO)-2-NAPHTHAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.266 |
| 1SQO Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2004-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
|
Not recorded | SO4 SULFATE ION × 3 UI2 8-(PYRIMIDIN-2-YLAMINO)NAPHTHALENE-2-CARBOXIMIDAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.84 Å R-free 0.284 |
| 1SQT Substituted 2-Naphthamidine Inhibitors of Urokinase Deposited 2004-03-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
|
Not recorded | UI3 7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å R-free 0.236 |
| 1U6Q Substituted 2-Naphthamadine inhibitors of Urokinase Deposited 2004-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–423（245 aa）
Fragment：Residues 179-423
|
Not recorded | 745 TRANS-6-(2-PHENYLCYCLOPROPYL)-NAPHTHALENE-2-CARBOXAMIDINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.02 Å R-free 0.290 |
| 1URK SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR Deposited 1994-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
26–155（130 aa）
|
Not recorded | FUC alpha-L-fucopyranose × 1 | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1VJ9 Urokinase Plasminogen Activator B-Chain-JT464 Complex Deposited 2004-02-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S | SO4 SULFATE ION × 2 5IN N-(BENZYLSULFONYL)-L-SERYL-N~1~-{4-[AMINO(IMINO)METHYL]BENZYL}-O-BENZYL-L-SERINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, lithium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.247 |
| 1VJA Urokinase Plasminogen Activator B-Chain-JT463 Complex Deposited 2004-02-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
164–425（262 aa）
Fragment：B Chain
|
Mutation：C122S | SO4 SULFATE ION × 2 7IN N-(BENZYLSULFONYL)SERYL-N~1~-{4-[(Z)-AMINO(IMINO)METHYL]BENZYL}SERINAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.2；277 K；sodium citrate, ammonium sulfate, lithium sulfate, pH 5.2, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å R-free 0.232 |
| 1W0Z Urokinase type plasminogen activator Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SI1 N-(BUTYLSULFONYL)-D-SERYL-N-{4-[AMINO(IMINO)METHYL]BENZYL}-L-ALANINAMIDE × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K
|
Resolution 1.90 Å R-free 0.221 |
| 1W10 Urokinase type plasminogen activator Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SJ1 N-(ISOBUTOXYCARBONYL)-D-SERYL-N-((1S)-4-{[AMINO(IMINO)METHYL]AMINO}-1-FORMYLBUTYL)-L-ALANINAMIDE × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K
|
Resolution 2.00 Å |
| 1W11 UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SO4 SULFATE ION × 2 SK1 N-(BENZYLSULFONYL)-D-SERYL-N-{4-[AMINO(IMINO)METHYL]BENZYL}-L-ALANINAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.249 |
| 1W12 UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SL1 N-((1S)-4-{[AMINO(IMINO)METHYL]AMINO}-1-FORMYLBUTYL)-2-{(3R)-3-[(BENZYLSULFONYL)AMINO]-2-OXO-5-PHENYL-2,3-DIHYDRO-1H-1,4-BENZODIAZEPIN-1-YL}ACETAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.40 Å R-free 0.261 |
| 1W13 UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SM1 N-(BENZYLSULFONYL)-D-SERYL-N-(4-{[AMINO(IMINO)METHYL]AMINO}BENZYL)-L-ALANINAMIDE × 1 SO4 SULFATE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.230 |
| 1W14 UROKINASE TYPE PLASMINOGEN ACTIVATOR Deposited 2004-06-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：RESIDUES 179-425
|
Not recorded | SO4 SULFATE ION × 2 SH1 N-[(2-PHENYLETHYL)SULFONYL]-D-SERYL-N-[(1S)-4-[(DIAMINOMETHYLENE)AMINO]-1-(HYDROXYMETHYL)BUTYL]-L-ALANINAMIDE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.253 |
| 2FD6 Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-upar antibody at 1.9 A Deposited 2005-12-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–152（122 aa）
Fragment：Amino terminal residues 31-152
|
Not recorded | SO4 SULFATE ION × 1 ETX 2-ETHOXYETHANOL × 3 EDO 1,2-ETHANEDIOL × 2 PGE TRIETHYLENE GLYCOL × 1 NDG 2-acetamido-2-deoxy-alpha-D-glucopyranose × 1 PG4 TETRAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 6.5；298 K；4% PEG4000, 5% ethylene glycol, 5% methanol, 0.05% sodium azide, 50 mM cacodylate, pH 6.5, MICRODIALYSIS, temperature 298K
|
Resolution 1.90 Å R-free 0.276 |
| 2FD6 Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-upar antibody at 1.9 A Deposited 2005-12-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–152（122 aa）
Fragment：Amino terminal residues 31-152
|
Not recorded | SO4 SULFATE ION × 1 ETX 2-ETHOXYETHANOL × 3 EDO 1,2-ETHANEDIOL × 2 PGE TRIETHYLENE GLYCOL × 1 NDG 2-acetamido-2-deoxy-alpha-D-glucopyranose × 1 PG4 TETRAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 6.5；298 K；4% PEG4000, 5% ethylene glycol, 5% methanol, 0.05% sodium azide, 50 mM cacodylate, pH 6.5, MICRODIALYSIS, temperature 298K
|
Resolution 1.90 Å R-free 0.276 |
| 2I9A Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF) Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 2I9A Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF) Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 2I9A Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF) Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 2I9A Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF) Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
21–163（143 aa）
Fragment：N-terminal fragment of urokinase, residues 21-163
|
Not recorded | PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 10.5；293 K；1.2 M sodium dihydrogen phosphate, 0.8 M potassium hydrogen phosphate, 200 mM lithium sulfate, 100 mM CHES, pH 10.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.208 |
| 2I9B Crystal structure of ATF-urokinase receptor complex Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.265 |
| 2I9B Crystal structure of ATF-urokinase receptor complex Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.265 |
| 2I9B Crystal structure of ATF-urokinase receptor complex Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.265 |
| 2I9B Crystal structure of ATF-urokinase receptor complex Deposited 2006-09-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
21–163（143 aa）
Fragment：ATF, residues 21-163
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；22.5% w/v PEG3350, 200 mM ammonium sulfate, 100 mM Bis-Tris, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.265 |
| 2VIN Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 SO4 SULFATE ION × 1 505 (2R)-1-(2,6-dimethylphenoxy)propan-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.05M COMPOUND, 27.5% PEG4000, 0.2M HEPES PH=6.6, 0.1M (NH4)(CH3COO)
|
Resolution 1.90 Å R-free 0.235 |
| 2VIO Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 L1O 4-(2-aminoethoxy)-3,5-dichlorobenzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.05M COMPOUND, 28% PEG4000, 0.29M HEPES PH=6.6, 5% GLYCEROL
|
Resolution 1.80 Å R-free 0.250 |
| 2VIP Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 SO4 SULFATE ION × 1 L1R 4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.01M COMPOUND, 28% PEG4000, 0.29M HEPES PH=6.6, 5% GLYCEROL, 0.001M NA(CH3COO), 0.001M (NH4)2SO4, 10% DMSO
|
Resolution 1.72 Å R-free 0.237 |
| 2VIQ Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 D55 4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.04M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 2.00 Å R-free 0.264 |
| 2VIV Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 VG2 4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.04M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 1.72 Å R-free 0.238 |
| 2VIW Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator Deposited 2007-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 179-431
|
Mutation：YES | ACT ACETATE ION × 1 D56 4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.6；PROTEIN WAS CRYSTALLIZED FROM 22-24% PEG4000, 0.17M (NH4)2SO4, 15% GLYCEROL, 0.1M NA(CH3COO) PH=4.0; THEN SOAKED IN 0.001M COMPOUND, 28% PEG4000, 5% GLYCEROL, 0.29M BISTRIS PH=6.6, 0.001M NA(CH3COO), 0.001M (NH4)2SO4
|
Resolution 2.05 Å R-free 0.260 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 SO4 SULFATE ION × 4 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 SO4 SULFATE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain E
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 SO4 SULFATE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 2VNT Urokinase-Type Plasminogen Activator Inhibitor Complex with a 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANIDINE Deposited 2008-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain F
156–431（276 aa）
Fragment：CATALYTIC DOMAIN, RESIDUES 156-431
|
Not recorded | QGG 1-({4-CHLORO-1-[(DIAMINOMETHYLIDENE)AMINO]ISOQUINOLIN-7-YL}SULFONYL)-D-PROLINE × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.20 Å R-free 0.295 |
| 3BT1 Structure of urokinase receptor, urokinase and vitronectin complex Deposited 2007-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；12% PEG 3350, 50mM HEPES pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.80 Å R-free 0.308 |
| 3BT2 Structure of urokinase receptor, urokinase and vitronectin complex Deposited 2007-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；8% PEG 4000, 2.5% ethanol, 0.05% sodium azide, 50mM cacodylate pH 6.5, pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.50 Å R-free 0.272 |
| 3BT2 Structure of urokinase receptor, urokinase and vitronectin complex Deposited 2007-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
21–153（133 aa）
Fragment：urokinase amino terminal fragment, Urokinase-type plasminogen activator long chain A, UNP residues 21-153
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICRODIALYSIS；pH 7.5；295 K；8% PEG 4000, 2.5% ethanol, 0.05% sodium azide, 50mM cacodylate pH 6.5, pH 7.5, MICRODIALYSIS, temperature 295K
|
Resolution 2.50 Å R-free 0.272 |
| 3KGP Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol Deposited 2009-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q | 4AZ 4-(aminomethyl)benzoic acid × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.35 Å R-free 0.274 |
| 3KHV Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic Acid and 4-(Aminomethyl-phenyl)-methanol Deposited 2009-10-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q | 4AL [4-(aminomethyl)phenyl]methanol × 1 SO4 SULFATE ION × 1 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.35 Å R-free 0.293 |
| 3KID The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator Deposited 2009-11-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q | 2BS ethyl 2-amino-1,3-benzothiazole-6-carboxylate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.60, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.71 Å R-free 0.275 |
| 3M61 Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition Deposited 2010-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
Fragment：C-terminal domain, UNP residues 179-431
|
Mutation：C122A, N145Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.60, 5% PEG 400, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.68 Å R-free 0.243 |
| 3MHW The complex crystal Structure of Urokianse and 2-Aminobenzothiazole Deposited 2010-04-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–425（247 aa）
Fragment：C-terminal domain, UNP residues 179-425
|
Mutation：C122S | SO4 SULFATE ION × 1 ABV 1,3-benzothiazol-2-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.45 Å R-free 0.234 |
| 3MWI The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine Deposited 2010-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：C-terminal domain, UNP residues 179-424
|
Mutation：C122A | B25 5-nitro-1H-indole-2-carboximidamide × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.05M sodium citrate, 1.95M (NH4)2SO4, 0.05% NaN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.03 Å R-free 0.297 |
| 3OX7 The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6 Deposited 2010-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, RESIDUES 179-431
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 PG4 TETRAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；0.05M SODIUM CITRATE, 1.95M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.58 Å R-free 0.230 |
| 3OY5 The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4 Deposited 2010-09-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, UNP residues 179-431
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；100mM Tris-Hcl, 2.0M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.31 Å R-free 0.231 |
| 3OY6 The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6 Deposited 2010-09-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
Fragment：C-TERMINAL DOMAIN, UNP residues 179-431
|
Mutation：C122A, N145Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；0.05M SODIUM CITRATE, 1.95M (NH4)2SO4, 0.05% NAN3, 5% PEG 400, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.31 Å R-free 0.263 |
| 3QN7 Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA) Deposited 2011-02-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–431（253 aa）
Fragment：Catalytic domain, Urokinase-type plasminogen activator chain B
|
Mutation：C122A, N145Q | ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.3；293 K；2M ammonium sulfate, 0.05M sodium citrate, 5%(v/v) PEG 400, pH 4.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.252 |
| 3U73 Crystal structure of stabilized human uPAR mutant in complex with ATF Deposited 2011-10-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
21–152（132 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；295 K；0.2M NaCl, 100mM HEPES, pH7.4, 1.8 M ammonium sulfate, vapor diffusion, sitting drop, temperature 295.0K
|
Resolution 3.19 Å R-free 0.258 |
| 4DVA The crystal structure of human urokinase-type plasminogen activator catalytic domain Deposited 2012-02-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：catalytic domain
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 P6G HEXAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, 5% PEG400, pH 4.6, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.94 Å R-free 0.244 |
| 4DW2 The crystal structure of uPA in complex with the Fab fragment of mAb-112 Deposited 2012-02-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain U
179–424（246 aa）
Fragment：catalytic domain, UNP RESIDUES 179-424
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；25% (w/v) PEG 2000 MME, 100mM Tris-HCl (pH 8.0), 0.21M ammonium sulfate, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.97 Å R-free 0.300 |
| 4FU7 Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | SO4 SULFATE ION × 3 ACT ACETATE ION × 1 1UP 2-[(7-carbamimidoyl-2-methoxynaphthalen-1-yl)oxy]acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.223 |
| 4FU8 Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 2UP naphthalene-2-carboximidamide × 1 ACT ACETATE ION × 2 SIN SUCCINIC ACID × 1 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.20 Å R-free 0.239 |
| 4FU9 Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | SO4 SULFATE ION × 3 SIN SUCCINIC ACID × 1 GOL GLYCEROL × 6 ACT ACETATE ION × 2 675 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291 - 298.0K
|
Resolution 1.60 Å R-free 0.182 |
| 4FUB Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 4UP 6-[(2S,3S)-3-phenyloxiran-2-yl]naphthalene-2-carboximidamide × 1 SO4 SULFATE ION × 1 SIN SUCCINIC ACID × 1 GOL GLYCEROL × 6 15P POLYETHYLENE GLYCOL (N=34) × 1 ACT ACETATE ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.90 Å R-free 0.187 |
| 4FUC Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 239 6-[(Z)-AMINO(IMINO)METHYL]-N-[4-(AMINOMETHYL)PHENYL]-2-NAPHTHAMIDE × 1 SIN SUCCINIC ACID × 1 SO4 SULFATE ION × 4 ACT ACETATE ION × 1 GOL GLYCEROL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.72 Å R-free 0.187 |
| 4FUD Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 6UP 8-aminonaphthalene-2-carboximidamide × 1 SIN SUCCINIC ACID × 3 SO4 SULFATE ION × 4 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å R-free 0.220 |
| 4FUE Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 7UP 6-(1,2,3,4-tetrahydroisoquinolin-6-ylethynyl)naphthalene-2-carboximidamide × 1 SIN SUCCINIC ACID × 1 SO4 SULFATE ION × 2 GOL GLYCEROL × 3 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å R-free 0.190 |
| 4FUF Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 8UP 8-(3-bromopropoxy)-7-methoxynaphthalene-2-carboximidamide × 1 SIN SUCCINIC ACID × 1 SO4 SULFATE ION × 3 GOL GLYCEROL × 4 ACT ACETATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å R-free 0.202 |
| 4FUG Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 9UP methyl (7-carbamimidoylnaphthalen-1-yl)carbamate × 1 SO4 SULFATE ION × 4 GOL GLYCEROL × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.80 Å R-free 0.203 |
| 4FUH Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 1U2 6-[(phenylcarbamoyl)amino]naphthalene-2-carboximidamide × 1 SO4 SULFATE ION × 4 ACT ACETATE ION × 1 GOL GLYCEROL × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.60 Å R-free 0.183 |
| 4FUI Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | UI3 7-METHOXY-8-[1-(METHYLSULFONYL)-1H-PYRAZOL-4-YL]NAPHTHALENE-2-CARBOXIMIDAMIDE × 1 SO4 SULFATE ION × 3 GOL GLYCEROL × 4 NA SODIUM ION × 1 SIN SUCCINIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 2.00 Å R-free 0.209 |
| 4FUJ Crystal Structure of the Urokinase Deposited 2012-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
179–424（246 aa）
|
Not recorded | 1U9 6-{(E)-2-[3-(2-hydroxyethyl)phenyl]ethenyl}naphthalene-2-carboximidamide × 1 SIN SUCCINIC ACID × 1 SO4 SULFATE ION × 2 ACT ACETATE ION × 2 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M Li2SO4, 20% polyethylene glycol MW 4000 in succinate buffer, pH 4.8-6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291 - 298.0K
|
Resolution 2.05 Å R-free 0.205 |
| 4GLY Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK504 Deposited 2012-08-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：CATALYTIC DOMAIN, UROKINASE-TYPE PLASMINOGEN ACTIVATOR
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 4 NA SODIUM ION × 2 CL CHLORIDE ION × 3 P6G HEXAETHYLENE GLYCOL × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；1.8M Ammonium sulfate, 5% PEG400, 0.05% Sodium azide, pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.52 Å R-free 0.204 |
| 4H42 Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA Deposited 2012-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–426（248 aa）
Fragment：human urokinase-type plasminogen activator catalytic domain
|
Mutation：C122A, N145Q | 11E N-[(2-amino-1,3-benzothiazol-6-yl)carbonyl]glycine × 1 PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 50 mM sodium citrate pH 4.6 and 5% PEG400, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å R-free 0.285 |
| 4JK5 Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Ser) Deposited 2013-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：Catalytic domain
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 4 CL CHLORIDE ION × 2 P6G HEXAETHYLENE GLYCOL × 1 ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；50mM Na3(cit) pH 4.9, 5% v/v PEG400, 1.8M (NH4)2SO4, 0.05% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.213 |
| 4JK6 Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18-D-Aba) Deposited 2013-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：Catalytic domain
|
Mutation：C299A, N322Q | SO4 SULFATE ION × 4 CL CHLORIDE ION × 1 P6G HEXAETHYLENE GLYCOL × 1 ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；50mM Na3(cit) pH 4.9, 5% v/v PEG400, 1.8M (NH4)2SO4, 0.05% NaN3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.205 |
| 4K24 Structure of anti-uPAR Fab ATN-658 in complex with uPAR Deposited 2013-04-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
21–153（133 aa）
Fragment：UNP residues 21-153
|
Not recorded | MAN alpha-D-mannopyranose × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；0.1M HEPES pH 7.5, 55%(v/v) Tacsimate, 2%(v/v) 2-methyl-1,3-propanediol, vapor diffusion, sitting drop, temperature 295K
|
Resolution 4.50 Å R-free 0.275 |
| 4MNV Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type plasminogen activator (uPA) Deposited 2013-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 ACT ACETATE ION × 2 ZBR 1,3,5-tris(bromomethyl)benzene × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；21% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.80 Å R-free 0.216 |
| 4MNW Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK749 Deposited 2013-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 GOL GLYCEROL × 5 ACT ACETATE ION × 1 ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；22% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.49 Å R-free 0.171 |
| 4MNX Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK811 Deposited 2013-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 GOL GLYCEROL × 1 29N 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tripropan-1-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；22% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.85 Å R-free 0.227 |
| 4MNY Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK903 Deposited 2013-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 ACT ACETATE ION × 2 GOL GLYCEROL × 2 29O N,N',N''-benzene-1,3,5-triyltris(2-bromoacetamide) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；20% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å R-free 0.215 |
| 4MNY Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK903 Deposited 2013-09-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 ACT ACETATE ION × 3 GOL GLYCEROL × 1 29O N,N',N''-benzene-1,3,5-triyltris(2-bromoacetamide) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.25；291 K；20% PEG4000, 16% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.25, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å R-free 0.215 |
| 4OS1 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK601 (bicyclic 1) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 ACT ACETATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.20 Å R-free 0.227 |
| 4OS2 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK602 (bicyclic 1) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.79 Å R-free 0.207 |
| 4OS4 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 1) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 GOL GLYCEROL × 1 ACT ACETATE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.214 |
| 4OS5 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK603 (bicyclic 2) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.26 Å R-free 0.200 |
| 4OS6 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK604 (bicyclic 2) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 2 ACT ACETATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.75 Å R-free 0.186 |
| 4OS7 Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK607 (bicyclic) Deposited 2014-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
179–423（245 aa）
Fragment：catalytic domain (UNP residues 179-423)
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 3 ACT ACETATE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；291 K；21% PEG4000, 15% glycerol, 0.17 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.00 Å R-free 0.198 |
| 4X0W The crystal structure of mupain-1-17 in complex with murinised human uPA Deposited 2014-11-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q | MRZ piperidine-1-carboximidamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 50 mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.10 Å R-free 0.272 |
| 4X1N The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4 Deposited 2014-11-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：C299A, H272Y, N322Q | MRZ piperidine-1-carboximidamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 1.80 Å R-free 0.276 |
| 4X1P The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6 Deposited 2014-11-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q | SO4 SULFATE ION × 2 PGE TRIETHYLENE GLYCOL × 2 MRZ piperidine-1-carboximidamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG400
|
Resolution 1.60 Å R-free 0.211 |
| 4X1Q The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4 Deposited 2014-11-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.28 Å R-free 0.287 |
| 4X1R The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4 Deposited 2014-11-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q | PL0 1-phenylguanidine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.10 Å R-free 0.273 |
| 4X1S The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4 Deposited 2014-11-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：catalytic domain (UNP RESIDUES 179-425)
|
Mutation：H99Y, C122A, N145Q | MRZ piperidine-1-carboximidamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 1.90 Å R-free 0.249 |
| 4XSK Structure of PAItrap, an uPA mutant Deposited 2015-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：UNP RESIDUES 162-407
|
Mutation：G37R, C122A, N145Q, S195A, R217L | SO4 SULFATE ION × 2 PGE TRIETHYLENE GLYCOL × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.2 M ammonium sulfate, 5% PEG 400, 50 mM sodium citrate (pH 4.6)
|
Resolution 1.50 Å R-free 0.209 |
| 4ZHL The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4 Deposited 2015-04-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400
|
Resolution 2.06 Å R-free 0.262 |
| 4ZHM The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4 Deposited 2015-04-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP RESIDUES 179-425
|
Mutation：H99Y, C122A, N145Q | MRZ piperidine-1-carboximidamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0M ammonium sulfate, 50mM sodium citrate, pH 4.6, 5% polyethylene glycol (PEG) 400
|
Resolution 1.90 Å R-free 0.264 |
| 4ZKN The crystal structure of upain-1-W3A in complex with uPA at pH5.5 Deposited 2015-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 PG4 TETRAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.36 Å R-free 0.265 |
| 4ZKO The crystal structure of upain-1-W3A in complex with uPA at pH7.4 Deposited 2015-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 P6G HEXAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.29 Å R-free 0.225 |
| 4ZKR The crystal structure of upain-1-W3A in complex with uPA at pH9.0 Deposited 2015-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q | SO4 SULFATE ION × 1 P6G HEXAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400
|
Resolution 1.36 Å R-free 0.234 |
| 4ZKS The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4 Deposited 2015-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–425（247 aa）
Fragment：UNP residues 179-425
|
Mutation：C122A, N145Q, S195A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；50 mM sodium citrate pH 4.6, 2.0 M ammonium sulfate supplemented with 5% PEG400
|
Resolution 1.85 Å R-free 0.245 |
| 5HGG Crystal structure of uPA in complex with a camelid-derived antibody fragment Deposited 2016-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
179–424（246 aa）
Fragment：UNP residues 179-424
Chain B
179–424（246 aa）
Fragment：UNP residues 179-424
|
Mutation：C122A, N145Q Mutation：C122A, N145Q | GOL GLYCEROL × 5 SO4 SULFATE ION × 2 TWN (3S)-3-[(2S,3S,4R)-3,4-DIMETHYLTETRAHYDROFURAN-2-YL]BUTYL LAURATE × 3 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.25；289 K；Sodium Phosphate dibasic, Ammonium Sulfate, MES, Tween 20
|
Resolution 1.97 Å R-free 0.196 |
| 5WXF Crystal structure of uPA in complex with upain-2-2 Deposited 2017-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.46 Å R-free 0.245 |
| 5WXO Crystal structure of uPA in complex with upain-2-2-W3A Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.64 Å R-free 0.221 |
| 5WXP Crystal structure of uPA in complex with upain-2-3-W3A Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | ALA ALANINE × 1 CYS CYSTEINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.75 Å R-free 0.249 |
| 5WXQ Crystal structure of uPA in complex with upain-2-4 Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.79 Å R-free 0.212 |
| 5WXR Crystal structure of uPA in complex with upain-2-4-W3A Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.75 Å R-free 0.234 |
| 5WXS Crystal structure of uPA in complex with S2444 Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q | 7YF (2R)-N-[2-[[(2S)-5-carbamimidamido-1-oxidanylidene-pentan-2-yl]amino]-2-oxidanylidene-ethyl]-5-oxidanylidene-1,2-dihydropyrrole-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.30 Å R-free 0.266 |
| 5WXT Crystal structure of uPA-S195A in complex with S2444 Deposited 2017-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C299A/N322Q/S376A | 7YR 5-oxo-D-prolylglycyl-N-(4-nitrophenyl)-L-argininamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.10 Å R-free 0.266 |
| 5XG4 Crystal structure of uPA in complex with quercetin Deposited 2017-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：UNP residues 179-424
|
Not recorded | QUE 3,5,7,3',4'-PENTAHYDROXYFLAVONE × 1 PG6 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 3.00 Å R-free 0.258 |
| 5YC6 The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6 Deposited 2017-09-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：Urokinase-type plasminogen activator chain B, UNP residues 179-324
|
Not recorded | PZH 1-(4-BROMOPHENYL)METHANAMINE × 1 SO4 SULFATE ION × 1 PGE TRIETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.18 Å R-free 0.228 |
| 5YC7 The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4 Deposited 2017-09-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
Fragment：Urokinase-type plasminogen activator chain B, UNP residues 179-324
|
Not recorded | PZH 1-(4-BROMOPHENYL)METHANAMINE × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 2.00 Å R-free 0.262 |
| 5Z1C The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4 Deposited 2017-12-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Mutation：C299U,N322U | ZXI 1-(4-iodophenyl)methanamine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate (pH 4.6), 2.0M ammonium sulfate supplemented with 5% PEG 400
|
Resolution 1.45 Å R-free 0.143 |
| 5ZA7 uPA-HMA Deposited 2018-02-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | HMX 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.70 Å R-free 0.227 |
| 5ZA8 uPA-BB2-27F Deposited 2018-02-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 27I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(1-methylpyrazol-4-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.90 Å R-free 0.233 |
| 5ZA9 uPA-BB2-50F Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 50I 3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.62 Å R-free 0.236 |
| 5ZAE uPA-6F-HMA Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | EAU 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.73 Å R-free 0.276 |
| 5ZAF uPA-BB2-28F Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
162–414（253 aa）
|
Mutation：C122A, N145Q | 28I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-3-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.65 Å R-free 0.236 |
| 5ZAG uPA-BB2-94F Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 94I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-pyrimidin-5-yl-pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.95 Å R-free 0.225 |
| 5ZAH uPA-BB2-30F Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 30I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 2.98 Å R-free 0.268 |
| 5ZAJ uPA-31F Deposited 2018-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 32I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.65 Å R-free 0.239 |
| 5ZC5 uPA-NU-09F Deposited 2018-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 09I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(4-fluoranyl-1-benzofuran-2-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.90 Å R-free 0.235 |
| 6AG2 uPA-HMA Deposited 2018-08-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 9X9 3,5-bis(azanyl)-N-carbamimidoyl-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0M ammonium sulfate, 50mM sodium citrate (pH 4.6), 5% PEG 400
|
Resolution 1.77 Å R-free 0.252 |
| 6AG3 Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide Deposited 2018-08-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 9XC 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 2.48 Å R-free 0.267 |
| 6AG7 The crystal structure of uPA in complex with HMA-55F Deposited 2018-08-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Not recorded | H55 3,5-diamino-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50 mM sodium citrate, pH 4.6, and 2.0 M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.90 Å R-free 0.228 |
| 6AG9 Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2- carboxamide Deposited 2018-08-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–431（253 aa）
|
Mutation：C122A, N145Q | 9XF 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate, pH 4.6, 2.0M ammonium sulfate supplemented with 5% polyethylene glycol 400
|
Resolution 1.63 Å R-free 0.206 |
| 6JYP Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide Deposited 2019-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
|
Mutation：H99Y,C122A,N145Q | HMX 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6-chloranyl-pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 2.25 Å R-free 0.254 |
| 6JYQ Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide Deposited 2019-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
|
Mutation：H99Y,C122A,N145Q | EAU 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.05M sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5% PEG 400
|
Resolution 1.75 Å R-free 0.263 |
| 6L04 Crystal structure of uPA_H99Y in complex with 31F Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Mutation：H99Y,C122A,N145Q | 32I 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-5-yl)pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400
|
Resolution 2.21 Å R-free 0.217 |
| 6L05 Crystal structure of uPA_H99Y in complex with 50F Deposited 2019-09-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Mutation：H99Y,C122A,N145Q | 50I 3-azanyl-5-(azepan-1-yl)-6-(1-benzofuran-2-yl)-Ncarbamimidoyl-pyrazine-2-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；50mM sodium citrate at pH 4.6, 1.95M (NH4)2SO4, 0.03% NaN3, 5%
PEG 400
|
Resolution 2.49 Å R-free 0.261 |
| 6NMB Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator Deposited 2019-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded | NO3 NITRATE ION × 1 AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å R-free 0.271 |
| 6NMB Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator Deposited 2019-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded | NO3 NITRATE ION × 1 AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å R-free 0.271 |
| 6NMB Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator Deposited 2019-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded | NO3 NITRATE ION × 1 AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å R-free 0.271 |
| 6NMB Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator Deposited 2019-01-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
164–431（268 aa）
Fragment：UNP residues 164-431
|
Not recorded | NO3 NITRATE ION × 1 AMH TRANS-4-AMINOMETHYLCYCLOHEXANE-1-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.03 M sodium nitrate, 0.03 M sodium phosphate, 0.03 M ammonium sulfate, 0.1 M Tris bicine, 25% v/v PEG500, 10% v/v PEG20000
|
Resolution 2.30 Å R-free 0.271 |
| 6XVD Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition Deposited 2020-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain U
162–414（253 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.05 M sodium citrate at pH 4.5, 1.95 M (NH4)2SO4, 0.05% NaN3, and 5% PEG400
|
Resolution 1.40 Å R-free 0.203 |
| 7DZD Crystal structure of uPA in complex with cleaved camostat Deposited 2021-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Mutation：C122A,N145Q | GBS 4-carbamimidamidobenzoic acid × 1 PGE TRIETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0M ammonium sulfate, 50mM sodium citrate pH 4.6, 5% PEG 400
|
Resolution 2.00 Å R-free 0.231 |
| 7VM4 Crystal structure of uPA in complex with nafamostat Deposited 2021-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Not recorded | GBS 4-carbamimidamidobenzoic acid × 1 PGE TRIETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；2.0 M ammonium sulfate, 5% PEG400, 20 mM sodium citrate, pH 4.6
|
Resolution 2.01 Å R-free 0.224 |
| 7VM5 Crystal structure of uPA in complex with 4-guanidinobenzoic acid Deposited 2021-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–424（246 aa）
|
Not recorded | PGE TRIETHYLENE GLYCOL × 1 GBS 4-carbamimidamidobenzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.97 Å R-free 0.247 |
| 7VM6 Crystal structure of uPA in complex with 6-amidino-2-naphthol Deposited 2021-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–426（248 aa）
|
Not recorded | 7R8 6-oxidanylnaphthalene-2-carboximidamide × 1 SO4 SULFATE ION × 1 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.79 Å R-free 0.243 |
| 7VM7 Crystal structure of inactive uPA in complex with nafamostat Deposited 2021-10-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain U
179–423（245 aa）
|
Not recorded | 7RF (6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；2.0 M ammonium sulfate, 5% PEG 400, 20 mM sodium citrate, pH 4.6
|
Resolution 1.87 Å R-free 0.242 |
| 7ZRR Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK965 Deposited 2022-05-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
154–431（278 aa）
|
Not recorded | 1PE PENTAETHYLENE GLYCOL × 1 EDO 1,2-ETHANEDIOL × 2 NH2 AMINO GROUP × 1 ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.3；293 K；5% PEG400, 50mM Citrato pH 4.3, 1.8 M (NH4)2SO4, 20% Ethylene glycol
|
Resolution 1.64 Å R-free 0.239 |
| 7ZRT Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inhibitor UK970 Deposited 2022-05-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
162–414（253 aa）
|
Not recorded | SO4 SULFATE ION × 2 PEG DI(HYDROXYETHYL)ETHER × 2 EDO 1,2-ETHANEDIOL × 3 1PE PENTAETHYLENE GLYCOL × 1 ZBR 1,3,5-tris(bromomethyl)benzene × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.3；293 K；7% PEG400, 50mM Citrato, 1.8 M (NH4)2SO4; 20% Ethylene glycol
|
Resolution 1.80 Å R-free 0.229 |
| 9PYF uPA Inhibitory Fab AB2 Complex Deposited 2025-08-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
156–425（270 aa）
|
Mutation：C122A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298.15 K；For crystallization purposes, uPA was co-incubated with AB2 in a 1:1 stoichiometric ratio for 1h and co-purified using size-exclusion chromatography. The complex co-eluted was concentrated to 15 mg/mL.Crystallization drops were produced by mixing 0.1 uL of uPA-AB2 solution with 0.1 uL of the respective crystallization solution. A single crystal was produced using a solution containing 0.2 M diammonium hydrogen citrate (Salt) and 20 percent PEG 3350 and incubating the experiment for 14 days at room temperature.
|
Resolution 2.90 Å R-free 0.300 |
147 other PDB entries and 165 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | UROK_HUMAN |
| Isoform | — |
| PDB entities | 1, 2 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–23； UniProt 156–178 Author chain B； PDBConstruct 1–253； UniProt 179–431 |
